Using multi-omics to develop the next generation of cancer therapeutics

Promatix is a data driven company that uses multi-omic information to develop a strong pipeline of novel therapeutics. We are particularly interested in the proteome, and using this in combination with other forms of omic information to gain insight into how these can vary in health and disease.

Our technology

Promatix's database, TxPro, has the largest known collection of proprietary proteomic data for oncology. Promatix mines TxPro to access novel drug targets that have the potential to transform the treatment of cancer.

Latest news

March 8, 2021

Promatix launches to develop next generation novel oncology therapeutics